Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation

Mimi C. Tan, Kavin A. Kanthasamy, Allison G. Yeh, Daniel Kil, Lisa Pompeii, Xiaoying Yu, Hashem B. El-Serag, Aaron P. Thrift

Research output: Contribution to journalArticle

Abstract

Background & Aims: Radiofrequency ablation (RFA) is effective treatment for Barrett's esophagus (BE). However, some patients have recurrence after complete eradication of intestinal metaplasia (CEIM). We investigated the incidence of and factors associated with BE recurrence, with or without neoplasia, after RFA and CEIM using data from the national Veterans Affairs (VA) healthcare system. Methods: We performed a retrospective cohort study of Veterans with BE treated by RFA from 2005 through 2016 with follow-up endoscopy. Subjects were followed until BE recurrence, neoplasia, death until October 2016. CEIM, BE recurrence, and factors associated with recurrence were identified by review of medical records. We calculated incidence rates of BE recurrence, with and without neoplasia, after CEIM and identified predictors using Cox proportional hazards models. Results: We identified 430 Veterans with BE who were treated with RFA; of these 337 achieved CEIM (78.4%). Most were men (98.6%), White (83.7%), and 66.0% had baseline dysplasia. Of those with CEIM, 98 patients (29.1%) had recurrence of BE during a total 906.0 patient-years of follow-up (median 1.9 years) after CEIM (incidence, 10.8%/patient-year). Dysplasia developed in 20 patients (2.2%/patient-year) and cancer in 3 patients (0.3%/patient-year). Baseline dysplasia (hazard ratio [HR], 1.71; 95% CI, 1.03–2.84) and long-segment BE (HR, 1.59; 95% CI, 1.01–2.51) increased risk of BE recurrence whereas treatment at high-volume RFA facilities reduced risk of BE recurrence (for quartile 4 vs quartile 1: HR, 0.19; 95% CI, 0.05–0.68). Conclusions: In a nationwide VA system study of outcomes of RFA for BE, we associated baseline dysplasia, long-segment BE, and treatment at low-volume RFA centers with recurrence of BE after CEIM. The findings call for performing these procedures in high-volume centers.

LanguageEnglish (US)
Pages65-72.e5
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Barrett Esophagus
Recurrence
Metaplasia
Veterans
Neoplasms
Incidence
Proportional Hazards Models
Endoscopy
Medical Records

Keywords

  • Dysplasia
  • Esophageal Cancer
  • Incidence
  • Intestinal Metaplasia

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. / Tan, Mimi C.; Kanthasamy, Kavin A.; Yeh, Allison G.; Kil, Daniel; Pompeii, Lisa; Yu, Xiaoying; El-Serag, Hashem B.; Thrift, Aaron P.

In: Clinical Gastroenterology and Hepatology, Vol. 17, No. 1, 01.01.2019, p. 65-72.e5.

Research output: Contribution to journalArticle

Tan, MC, Kanthasamy, KA, Yeh, AG, Kil, D, Pompeii, L, Yu, X, El-Serag, HB & Thrift, AP 2019, 'Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation', Clinical Gastroenterology and Hepatology, vol. 17, no. 1, pp. 65-72.e5. https://doi.org/10.1016/j.cgh.2018.05.042
Tan, Mimi C. ; Kanthasamy, Kavin A. ; Yeh, Allison G. ; Kil, Daniel ; Pompeii, Lisa ; Yu, Xiaoying ; El-Serag, Hashem B. ; Thrift, Aaron P. / Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. In: Clinical Gastroenterology and Hepatology. 2019 ; Vol. 17, No. 1. pp. 65-72.e5.
@article{79ca9c9cb9e34313b7a9d8eabf468361,
title = "Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation",
abstract = "Background & Aims: Radiofrequency ablation (RFA) is effective treatment for Barrett's esophagus (BE). However, some patients have recurrence after complete eradication of intestinal metaplasia (CEIM). We investigated the incidence of and factors associated with BE recurrence, with or without neoplasia, after RFA and CEIM using data from the national Veterans Affairs (VA) healthcare system. Methods: We performed a retrospective cohort study of Veterans with BE treated by RFA from 2005 through 2016 with follow-up endoscopy. Subjects were followed until BE recurrence, neoplasia, death until October 2016. CEIM, BE recurrence, and factors associated with recurrence were identified by review of medical records. We calculated incidence rates of BE recurrence, with and without neoplasia, after CEIM and identified predictors using Cox proportional hazards models. Results: We identified 430 Veterans with BE who were treated with RFA; of these 337 achieved CEIM (78.4{\%}). Most were men (98.6{\%}), White (83.7{\%}), and 66.0{\%} had baseline dysplasia. Of those with CEIM, 98 patients (29.1{\%}) had recurrence of BE during a total 906.0 patient-years of follow-up (median 1.9 years) after CEIM (incidence, 10.8{\%}/patient-year). Dysplasia developed in 20 patients (2.2{\%}/patient-year) and cancer in 3 patients (0.3{\%}/patient-year). Baseline dysplasia (hazard ratio [HR], 1.71; 95{\%} CI, 1.03–2.84) and long-segment BE (HR, 1.59; 95{\%} CI, 1.01–2.51) increased risk of BE recurrence whereas treatment at high-volume RFA facilities reduced risk of BE recurrence (for quartile 4 vs quartile 1: HR, 0.19; 95{\%} CI, 0.05–0.68). Conclusions: In a nationwide VA system study of outcomes of RFA for BE, we associated baseline dysplasia, long-segment BE, and treatment at low-volume RFA centers with recurrence of BE after CEIM. The findings call for performing these procedures in high-volume centers.",
keywords = "Dysplasia, Esophageal Cancer, Incidence, Intestinal Metaplasia",
author = "Tan, {Mimi C.} and Kanthasamy, {Kavin A.} and Yeh, {Allison G.} and Daniel Kil and Lisa Pompeii and Xiaoying Yu and El-Serag, {Hashem B.} and Thrift, {Aaron P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cgh.2018.05.042",
language = "English (US)",
volume = "17",
pages = "65--72.e5",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation

AU - Tan, Mimi C.

AU - Kanthasamy, Kavin A.

AU - Yeh, Allison G.

AU - Kil, Daniel

AU - Pompeii, Lisa

AU - Yu, Xiaoying

AU - El-Serag, Hashem B.

AU - Thrift, Aaron P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background & Aims: Radiofrequency ablation (RFA) is effective treatment for Barrett's esophagus (BE). However, some patients have recurrence after complete eradication of intestinal metaplasia (CEIM). We investigated the incidence of and factors associated with BE recurrence, with or without neoplasia, after RFA and CEIM using data from the national Veterans Affairs (VA) healthcare system. Methods: We performed a retrospective cohort study of Veterans with BE treated by RFA from 2005 through 2016 with follow-up endoscopy. Subjects were followed until BE recurrence, neoplasia, death until October 2016. CEIM, BE recurrence, and factors associated with recurrence were identified by review of medical records. We calculated incidence rates of BE recurrence, with and without neoplasia, after CEIM and identified predictors using Cox proportional hazards models. Results: We identified 430 Veterans with BE who were treated with RFA; of these 337 achieved CEIM (78.4%). Most were men (98.6%), White (83.7%), and 66.0% had baseline dysplasia. Of those with CEIM, 98 patients (29.1%) had recurrence of BE during a total 906.0 patient-years of follow-up (median 1.9 years) after CEIM (incidence, 10.8%/patient-year). Dysplasia developed in 20 patients (2.2%/patient-year) and cancer in 3 patients (0.3%/patient-year). Baseline dysplasia (hazard ratio [HR], 1.71; 95% CI, 1.03–2.84) and long-segment BE (HR, 1.59; 95% CI, 1.01–2.51) increased risk of BE recurrence whereas treatment at high-volume RFA facilities reduced risk of BE recurrence (for quartile 4 vs quartile 1: HR, 0.19; 95% CI, 0.05–0.68). Conclusions: In a nationwide VA system study of outcomes of RFA for BE, we associated baseline dysplasia, long-segment BE, and treatment at low-volume RFA centers with recurrence of BE after CEIM. The findings call for performing these procedures in high-volume centers.

AB - Background & Aims: Radiofrequency ablation (RFA) is effective treatment for Barrett's esophagus (BE). However, some patients have recurrence after complete eradication of intestinal metaplasia (CEIM). We investigated the incidence of and factors associated with BE recurrence, with or without neoplasia, after RFA and CEIM using data from the national Veterans Affairs (VA) healthcare system. Methods: We performed a retrospective cohort study of Veterans with BE treated by RFA from 2005 through 2016 with follow-up endoscopy. Subjects were followed until BE recurrence, neoplasia, death until October 2016. CEIM, BE recurrence, and factors associated with recurrence were identified by review of medical records. We calculated incidence rates of BE recurrence, with and without neoplasia, after CEIM and identified predictors using Cox proportional hazards models. Results: We identified 430 Veterans with BE who were treated with RFA; of these 337 achieved CEIM (78.4%). Most were men (98.6%), White (83.7%), and 66.0% had baseline dysplasia. Of those with CEIM, 98 patients (29.1%) had recurrence of BE during a total 906.0 patient-years of follow-up (median 1.9 years) after CEIM (incidence, 10.8%/patient-year). Dysplasia developed in 20 patients (2.2%/patient-year) and cancer in 3 patients (0.3%/patient-year). Baseline dysplasia (hazard ratio [HR], 1.71; 95% CI, 1.03–2.84) and long-segment BE (HR, 1.59; 95% CI, 1.01–2.51) increased risk of BE recurrence whereas treatment at high-volume RFA facilities reduced risk of BE recurrence (for quartile 4 vs quartile 1: HR, 0.19; 95% CI, 0.05–0.68). Conclusions: In a nationwide VA system study of outcomes of RFA for BE, we associated baseline dysplasia, long-segment BE, and treatment at low-volume RFA centers with recurrence of BE after CEIM. The findings call for performing these procedures in high-volume centers.

KW - Dysplasia

KW - Esophageal Cancer

KW - Incidence

KW - Intestinal Metaplasia

UR - http://www.scopus.com/inward/record.url?scp=85058393288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058393288&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2018.05.042

DO - 10.1016/j.cgh.2018.05.042

M3 - Article

VL - 17

SP - 65-72.e5

JO - Clinical Gastroenterology and Hepatology

T2 - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 1

ER -